Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
about
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin.
P2860
Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Sodium-glucose co-transporter- ...... tic review of current evidence
@ast
Sodium-glucose co-transporter- ...... tic review of current evidence
@en
Sodium-glucose co-transporter- ...... tic review of current evidence
@nl
type
label
Sodium-glucose co-transporter- ...... tic review of current evidence
@ast
Sodium-glucose co-transporter- ...... tic review of current evidence
@en
Sodium-glucose co-transporter- ...... tic review of current evidence
@nl
prefLabel
Sodium-glucose co-transporter- ...... tic review of current evidence
@ast
Sodium-glucose co-transporter- ...... tic review of current evidence
@en
Sodium-glucose co-transporter- ...... tic review of current evidence
@nl
P2860
P356
P1476
Sodium-glucose co-transporter- ...... tic review of current evidence
@en
P2093
Awadhesh Kumar Singh
Ritu Singh
P2860
P304
P356
10.4103/2230-8210.176353
P407
P577
2016-01-01T00:00:00Z